ALX-0761: Phase I started

Ablynx said Merck's Merck Serono S.A. unit began a double-blind, placebo-controlled Phase I trial to evaluate single ascending-doses of subcutaneous ALX-0761 in healthy volunteers. The start triggers a €2.5 million ($3.3 million) milestone payment to Ablynx under a 2008 deal in which Ablynx and Merck Serono partnered to co-discover and co-develop Ablynx 's Nanobodies against 2 undisclosed targets in cancer and immunology (see BioCentury, Sept. 8, 2008). ...